Ryvu Therapeutics SA
F:9Y4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ryvu Therapeutics SA
F:9Y4
|
PL |
Intrinsic Value
The intrinsic value of Ryvu Therapeutics SA (9Y4) under the Base Case is 4.122 EUR per share. Compared with the current market price of 3.795 EUR, the stock appears Undervalued by 8% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Ryvu Therapeutics Does
Ryvu Therapeutics is a biotechnology company that discovers and develops medicines for cancer. Its work centers on small-molecule drugs and other targeted therapies designed to interfere with the biology that helps tumor cells grow and survive. The company does not sell everyday products; it builds a pipeline of experimental drug candidates and advances them through laboratory testing and clinical trials.
- Headquarters
- Poland PL
- Employees
- 186
- IPO date
- Jul 14, 2011
Revenue & Expenses Breakdown
Ryvu Therapeutics SA
Earnings Waterfall
Ryvu Therapeutics SA
The intrinsic value for Ryvu Therapeutics SA (9Y4) under the Base Case is 4.122 EUR.
Compared with the current market price of 3.795 EUR, the stock appears Undervalued by 8% .